baber/WOPTO huggingface dataset:
Patent JP-3505052-B2 (JP)
IPC: C09K23/52
Filed: 1996-12-02
Granted: 2004-03-08
Abstract: Polyamino acid-based copolymers are claimed which contain at least 75 wt.% of units of formula -NH-A(COOR1)-CO- (I) and -NH-B-CO- (II), there being at least 3 units of formula (I) present with at least one R1 = (a) and at least one R1 = (b) or (c) and there also being present at most 20 wt.% of formula (II) units derived from proteinogenic or non-proteinogenic amino acids. A = 2 or 3C trifunctional hydrocarbon group; and R1 = (a), (b) or (c). (a) = R2 which is an alkali(ne earth), metal, H or (NR5R6R7R8)+ where R5- R8 = H, alkyl or hydroxyalkyl; (b) = R3 which is an optionally unsaturated 6-24C group (R9) or -X-R9, with X = oligo or poly-oxyalkylene chain with 1-100 oxyalkylene units; and (c) = R4 which is a 1-5C optionally unsaturated alkyl. Also claimed is the preparation of the claimed copolymers comprising reacting esters of  alpha , beta -unsaturated, dicarboxylic acids (or ammonium salts), preferred maleic acid derivatives, of formula (III) and/or (IV) with ammonia and polymerising, optionally in presence of up to 20 wt.% proteinogenic or non-proteinogenic amino acids or derivatives, and optionally also with the further step of hydrolysing the groups of formula (I) to make R1 = R2. Z = H and/or ammonium. Other copolymers can be obtained by reaction of polyaspartimide with R4OH, optionally followed by reaction with R3OH and optionally also by hydrolysis of the production.
Patent JP-3153365-B2 (JP)
IPC: C12R1/38
Filed: 1992-12-02
Granted: 2001-04-09
Abstract: A novel microbiological process for the preparation of hydroxylated heterocyclic carboxylic acids of the formula <IMAGE> starts from the corresponding heterocyclic carboxylic acid. This process is carried out in such a way that a) aerobic biomass which utilises nicotinic acid is cultivated in a molar ratio of nicotinic acid to mineral acid of 1 to 8, this ratio being ensured throughout the culture period, and then b) the hydroxylation of the corresponding heterocyclic carboxylic acid of the general formula. <IMAGE> in which R1 and X have the said meaning, is carried out with this biomass. Under these conditions it is possible in the culture period to accumulate microorganisms of the species Pseudomonas acidovorans DSM 7205, of the species Pseudomonas acidovorans DSM 7203, of the species Alcaligenes faecalis DSM 7204 and microorganisms with the identifier DSM 7202.
Patent JP-2920611-B2 (JP)
IPC: A61K47/48
Filed: 1995-12-11
Granted: 1999-07-19
Abstract: The present invention provides an external therapeutic composition for dermatitis comprising an aqueous solution including a therapeutically effective amount of an adrenal cortical steroid, a cyclodextrin, polysaccharides, and a carrier such as water, prepared by clathrating the adrenal cortical steroid in the cyclodextrin using a homomixer to form a clathrate, and adding the clathrate to an aqueous solution of polysaccharides, while being stirred uniformly, to dissolve the clathrate in the aqueous solution, as well as a method for the treatment of dermatitis in a mammalian subject, which comprises administering to said subject a therapeupically effective amount of the external therapeutic composition for dermatitis described above. The external therapeutic composition for dermatitis according to the present invention is extremely safe and can cure dermatitis such as an atopic dermatitis or the like without side effects.
Patent JP-H0761056-B2 (JP)
IPC: H04J3/07
Filed: 1990-12-27
Abstract: This device essentially comprises a so-called elastic memory, of specified capacity for holding, at each instant defined by a reduced insertion rate D2/n, binary elements constituting words read from a buffer-memory written to at a reduced rate D1/n, and which have not yet been inserted or have not yet been reinserted into the outgoing frames, and variable in number, dependent upon justifying commands generated earlier, means of selecting binary elements held in this elastic memory, for insertion or reinsertion into the outgoing frames, and means of temporarily freezing the buffer-memory reading clock when the number of binary elements to be stored in the elastic memory exceeds a predetermined limit fill value for this memory. <IMAGE>
Patent JP-2756162-B2 (JP)
IPC: C07K16/40
Filed: 1988-11-02
Granted: 1998-05-25
Abstract: A method for purifying a recombinant protein, e.g. human tissue plasminogen activator (t-PA) from a corresponding endogenous protein of the host cell, e.g. Chinese hamster t-PA, is disclosed. The method comprises contacting a fluid containing the recombinant protein with antibodies specifically binding the corresponding endogenous protein. Monoclonal antibodies directed against and an assay for Chinese hamster t-PA are also disclosed.
Patent JP-4423680-B2 (JP)
IPC: A61K39/395
Filed: 1996-06-06
Granted: 2010-03-03
Abstract: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
Patent JP-3483255-B2 (JP)
IPC: A61L15/32
Filed: 1994-06-03
Granted: 2004-01-06
Abstract: A formulated biological adhesive composition utilizes tissue transglutaminase in a pharmaceutically acceptable aqueous carrier. The tissue transglutaminase is used in an effective catalytic amount to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue and/or the enzyme. The carrier contains a divalent metal ion such as calcium to promote said reaction.
Patent JP-4146514-B2 (JP)
IPC: A61K31/505
Filed: 1996-06-24
Granted: 2008-09-10
Abstract: PCT No. PCT/EP96/02728 Sec. 371 Date Jan. 26, 1998 Sec. 102(e) Date Jan. 26, 1998 PCT Filed Jun. 24, 1996 PCT Pub. No. WO97/02266 PCT Pub. Date Jan. 23, 1997Described are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols are as defined in claim 1. Those compounds inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumour diseases.
Patent JP-H0819663-B2 (JP)
IPC: E21B49/00
Filed: 1990-05-25
Abstract: PCT No. PCT/FR90/00368 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed May 25, 1990 PCT Pub. No. WO90/15324 PCT Pub. Date Dec. 13, 1990.An improved method and apparatus for performing pressiometric tests are disclosed, wherein an expansible or inflatable sensor is introduced into a borehole, liquid is supplied to saturate the surrounding ground, and a ground characteristic is measured by monitoring changes in the pressure and volume of the sensor. Thereby, the tendency of the ground to heave is measured.
Patent JP-4004551-B2 (JP)
IPC: A61M1/28
Filed: 1998-07-06
Granted: 2007-11-07
Abstract: Methods and apparatus are disclosed for testing the integrity of a tube set used in a cycler for peritoneal dialysis comprising a closable housing for at least a portion of the tube set and an air pump for subjecting the housing to an underpressure or an overpressure, and clamps for clamping portions of the tube set passing into the housing. The method includes subjecting the housing to a first overpressure with the clamps closed whereby a first pressure leakage is observed, subjecting the housing to a second overpressure with the clamps open whereby a second pressure leakage is observed, and comparing the first and second pressure leakages so that action can be taken based upon that comparison.
Patent JP-2577842-B2 (JP)
IPC: A61B17/22
Filed: 1991-05-17
Granted: 1997-02-05
Abstract: A guidewire and guidewire assembly (10) for placement within a blood vessel for penetrating an occlusion therein. The guidewire comprises a length of flexible wire (12) having a concentric lumen (14) running its entire length and a distal end portion (20) having an arcuate tip (22) and a diameter greater than that of the wire immediately proximal thereto. The guidewire assembly comprises the guidewire described along with a flexible stylet (32) substantially the same length as the flexible wire and disposed within the lumen of the wire. In operation, the distal end portion is positioned in the blood vessel against an occlusion, and a dottering action is thereafter provided whereby the distal end portion repeatedly impinges on the occlusion until penetration of the occlusion occurs.
Patent JP-3357359-B2 (JP)
IPC: A61P37/00
Filed: 1990-08-31
Granted: 2002-12-16
Abstract: The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand. The invention is based upon the discovery that the  alpha 4 beta 1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the  alpha 4 beta 1 receptor had not been identified, nor had the function of the  alpha 4 beta 1 receptor in lymphocyte attachment been known. By preventing the interaction between the  alpha 4 beta 1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues. The present invention, therefore, has particular clinical utility in suppression of the immune response, in various specific embodiments of the invention, the adherence of lymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localized to particular tissues or circumscribed areas. Accordingly, the present invention provides for treatment of diseases involving autoimmune responses as well as other chronic or relapsing activations of the immune system, including allergy, asthma, and chronic inflammatory skin conditions.
Patent JP-2870666-B2 (JP)
IPC: G11B19/20
Filed: 1995-10-05
Granted: 1999-03-17
Abstract: A disk drive contains an integrally-formed one-piece hub, clamp and rotor housing, which is preferably injection-molded plastic. In the preferred embodiment, the hub includes a hollow cylindrical portion for surrounding a set of bearings mounted on a central shaft, and a flange portion extending from the middle of the cylinder and supporting a single disk. Compliant clamping fingers on the upper surface of the flange engage the disk through its central hole. The fingers are inclined slightly outward, and include a pawl at the end of each finger. During assembly, the disk is forced over the pawls of the fingers until they engage the disk. The fingers, being slightly elastic, will deform to permit the disk to slide over the pawls, and then return to lock the disk in place. The fingers automatically center the disk about the hub axis, without the need for centering tools. The hub also serves as a housing for the rotor of a spindle motor which rotates the disk. A back iron ring and permanent magnets are attached to the underside of the flange at its outer edge to form the rotor. An electromagnetic stator assembly surrounds the disk axis in the annular space defined by the flange, the permanent magnets and back iron at the outer edge, and the cylindrical portion of the hub at the inner edge.
Patent JP-3181585-B2 (JP)
IPC: A61K47/42
Filed: 1991-07-30
Granted: 2001-07-03
Abstract: PCT No. PCT/FR91/00630 Sec. 371 Date Feb. 1, 1993 Sec. 102(e) Date Feb. 1, 1993 PCT Filed Jul. 30, 1991 PCT Pub. No. WO92/02209 PCT Pub. Date Feb. 20, 1992.The present invention relates to a process for preparing a bioadhesive sustained-release pharmaceutical dosage form, characterized in that: a) at least a part of the active principles is mixed with a quantity of natural proteins representing at least 50% by weight of active principle, and with 0.5 to 10% of a hydrophilic polymer, b) the mixture obtained at the end of step a is subjected to granulation in the presence of approximately 60 DEG  strength alcohol, followed by drying to bring it to a moisture content of approximately 3%. c) the granules thereby obtained, after sizing, are mixed with standard formulation excipients, especially ballast materials, lubricants, flavorings and sweeteners, d) the mixture obtained at the end of step c, is subjected to tabletting for the purpose of obtaining bioadhesive sustained-release tablets. It also relates to a pharmaceutical dosage form displaying long-lasting properties of adhesiveness to the mucosae.
Patent JP-3612073-B2 (JP)
IPC: A61P31/04
Filed: 1994-11-03
Granted: 2005-01-19
Abstract: PCT No. PCT/US94/12575 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Nov. 3, 1994 PCT Pub. No. WO95/14670 PCT Pub. Date Jun. 1, 1995The present invention relates to heterocyclic benzenesulfonylimine derivatives and their use as inhibitors of Interleukin-1 (IL-1) action. Such inhibitors are useful in the treatment of various disease states as disclosed herein including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, atherosclerosis, septic shock and pulmonary fibrosis.
Patent JP-3218043-B2 (JP)
IPC: D04H1/542
Filed: 1996-01-03
Granted: 2001-10-15
Abstract: The invention relates to an insulation product and a method for producing the same. The insulation product comprises a base material of cellulosic pulp wool and a bonding agent bonded with an adhesive to the cellulosic pulp wool. The invention is characterized in that the bonding agent is viscose fibre and the adhesive is of a cellulose-based material.
Patent JP-4058502-B2 (JP)
IPC: B23K20/10
Filed: 1996-11-26
Granted: 2008-03-12
Abstract: PCT No. PCT/SE96/01547 Sec. 371 Date Jun. 10, 1998 Sec. 102(e) Date Jun. 10, 1998 PCT Filed Nov. 26, 1996 PCT Pub. No. WO97/21535 PCT Pub. Date Jun. 19, 1997The present invention relates to a method of welding or cutting material ultrasonically while avoiding hammering motion between ultrasonic anvil and ultrasonic horn, so-called cobblestoning. The material web is welded or cut generally transversely to its direction of movement, wherein at least one elongated ultrasonic horn is positioned obliquely to the direction of web movement, and at least on anvil corresponding to the ultrasonic horn is arranged on a rotatable cylinder whose rotational axis is essentially parallel with the longitudinal axis of the ultrasonic horn.
Patent JP-4037453-B2 (JP)
IPC: C23F13/00
Filed: 1997-01-31
Granted: 2008-01-23
Abstract: PCT No. PCT/GB97/00293 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/29220 PCT Pub. Date Aug. 14, 1997An electrochemical electrode of a tube of porous titanium suboxide with a contact connection to an electrical supply.
Patent JP-4267696-B2 (JP)
IPC: A23K1/165
Filed: 1997-02-28
Granted: 2009-05-27
Abstract: The present invention relates to an enzyme with galactanase activity, a DNA construct encoding the enzyme with galactanase activity, a method of producing the enzyme, an enzyme composition comprising the enzyme with galactanase activity, and the use of the galactanase enzyme and enzyme composition for a number of industrial applications.
Patent JP-3822248-B2 (JP)
IPC: B25D17/06
Filed: 1997-05-06
Granted: 2006-09-13
Abstract: The present invention relates to a hammer device, preferably a down-the-hole hammer, including a drill bit (11) and a piston (10) reciprocating therebehind to periodically strike the drill bit. The drill bit (11) includes front (11a) and rear (11b) portions of different impedance, and the piston (10) includes front (10b) and rear (10a) portions of different impedance. In the drill bit, the front portion (11a) has a larger impedance than the rear portion (11b). In the piston, the rear portion (10a) has a larger impedance than the front portion (10b). The length of the drill bit front portion (11a) is about twice the length of the drill bit rear portion (11b). The length of the piston rear portion (10a) is about twice the length of the piston front portion (11b). The invention further relates to a drill bit (11) and a piston (10), per se.
Patent AU-2001286966-B2 (AU)
Title: Method for analysis of oligonucleotide analogs
Inventor: WELLER DWIGHT D
IPC: C12Q1/6832
Filed: 2001-08-30
Granted: 2007-03-01
Abstract: Disclosed are methods for separating, detecting, quantitating and/or isolating predominantly uncharged oligonucleotide analogs, by resolving duplexes of such molecules with complementary or near-complementary DNA or charged DNA analogs. The DNA or charged analog may be labeled for detection purposes.
Patent AU-2002217383-B2 (AU)
Title: Polyurethane compositions useful as shock absorbers and a method for their preparation
Inventor: EM NEHEMYA RE
IPC: C08G18/48
Filed: 2001-12-19
Granted: 2006-10-05
Abstract: A polyurethane foam composition comprising at least: at least one polyether polyol having an average molecular weight from 100-20,000; an aromatic polyisocyanate; a tackifying resin; a surfactant; a blowing agent, and a catalyst. A method for preparation of a polyurethane foam composition useful in shock absorption, is also disclosed.
Patent AU-2002240774-B2 (AU)
Title: A Method for Establishing an IPOA Channel-Based Operation and Maintenance Channel
Inventor: PENG JIANHUA
IPC: H04W92/12
Filed: 2002-03-13
Granted: 2007-07-26
Abstract: This invention discloses a method for establishing IPOA channel-based default maintenance channels. The invention establishes an IPOA channel between a base station and a base station controller with default configuration of the base station. A BOOTP request is initiated from the base station to an operation and maintenance center, and the base station obtains an IP address assigned to it from a response sent from the operation and maintenance center, so that an operation and maintenance channel is established between the base station and the base station controller. The invention can solve automatic base station launching problem, and can prevent IP address conflicts and implement parallel launching of base stations. In addition, with the method described in this invention, operation of establishing maintenance channels is simple, light in workload, and reliable. Thus, program and data auto-loading as well as configuration and maintenance of base station(s) at far end (i.e., the operation and maintenance center) can be achieved. The method described in this invention is superior in quality and low cost in maintenance, and can be applied to various networking patterns, such as star-type, chain-type, and tree-type networks. <IMAGE>
Patent AU-2002249812-B2 (AU)
Title: Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
Inventor: GARVEY DAVID S
IPC: A61P7/02
Filed: 2001-12-21
Granted: 2005-11-10
Abstract: The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal anti-inflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton-pump-inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity or other toxicities; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
Patent AU-2002252258-B2 (AU)
Title: Ultra-low shrinkage composite resins based on blended nematic liquid crystal monomers
Inventor: NEERA SATSANGI
IPC: A61K6/884
Filed: 2002-03-07
Granted: 2006-09-07
Abstract: Liquid crystal monomers and secondary monomers useful to blend with liquid crystal monomers to maintain a nematic state under processing conditions while maintaining low cure shrinkage, particularly suitable for use in dental resin composites.
Patent AU-2002332628-B2 (AU)
Title: Human antibodies specific for interleukin 15 (IL-15)
Inventor: DIJK MARCUS ANTONIUS VAN
IPC: C12P21/08
Filed: 2002-08-23
Granted: 2007-07-26
Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Patent AU-2002340487-B2 (AU)
Title: Process for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine)
Inventor: CANNATA VINCENZO
IPC: C07D413/04
Filed: 2002-10-29
Granted: 2007-12-13
Abstract: A process and new oxazolinic intermediates for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-clohepta-[1,2-b]-pyridin-11-ylide-ne)-1-piperidinecarboxylic acid ethyl ester (loratadine) is described. The process starts from 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine, a new intermediate to obtain loratadine. 2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-3-methyl-pyridine is condensed with 3-chloro-benzyl-chloride and the resultant product is treated with Grignard reagent of 4-chloro-N-methyl-piperidine. [3-(2-(3-chloro-phenyl)-ethyl]-pyridin-2-yl-]-1-(methyl-piperidin-4-yl)-methanone is obtained for subsequent hydrolysis. Starting from this last compound it is possible to obtain loratadine with known methods.
Patent AU-2002341594-B2 (AU)
Title: Bobbin for automatic inflator
Inventor: FAWCETT LYMAN W JR
IPC: F16K31/00
Filed: 2002-09-04
Granted: 2008-08-07
Abstract: An automatic inflator comprising a body for receiving a dissolvable pill, said dissolvable pill including an upper surface and a lower surface, at least one of said surfaces including an undulating configuration.